



HAL
open science

COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms

Marek Ostaszewski, Anna Niarakis, Alexander Mazein, Inna Kuperstein, Robert Phair, Aurelio Orta-Resendiz, Vidisha Singh, Sara Sadat Aghamiri, Marcio Luis Acencio, Enrico Glaab, et al.

► **To cite this version:**

Marek Ostaszewski, Anna Niarakis, Alexander Mazein, Inna Kuperstein, Robert Phair, et al.. COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms. 2021. hal-03385317v1

HAL Id: hal-03385317

<https://hal.science/hal-03385317v1>

Preprint submitted on 24 Feb 2021 (v1), last revised 19 Oct 2021 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms

Marek Ostaszewski¹, Anna Niarakis^{2,3}, Alexander Mazein¹, Inna Kuperstein^{4,5,6}, Robert Phair⁷, Aurelio Orta-Resendiz^{8,9}, Vidisha Singh², Sara Sadat Aghamiri¹⁰, Marcio Luis Acencio¹, Enrico Glaab¹, Andreas Ruepp¹¹, Gisela Fobo¹¹, Corinna Montrone¹¹, Barbara Brauner¹¹, Goar Frishman¹¹, Luis Cristóbal Monraz Gómez^{4,5,6}, Julia Somers¹², Matti Hoch¹³, Shailendra Kumar Gupta¹³, Julia Scheel¹³, Hanna Borlinghaus¹⁴, Tobias Czauderna¹⁵, Falk Schreiber^{14,15}, Arnau Montagud¹⁶, Miguel Ponce de Leon¹⁶, Akira Funahashi¹⁷, Yusuke Hiki¹⁷, Noriko Hiroi^{17,18}, Takahiro G. Yamada¹⁷, Andreas Dräger^{19,20,21}, Alina Renz^{19,20}, Muhammad Naveez^{13,22}, Zsolt Bocskei²³, Francesco Messina^{24,25}, Daniela Börnigen²⁶, Liam Fergusson²⁷, Marta Conti²⁸, Marius Rameil²⁸, Vanessa Nakonecnij²⁸, Jakob Vanhoefer²⁸, Leonard Schmiester^{28,30}, Muying Wang³¹, Emily E. Ackerman³¹, Jason Shoemaker^{31,32}, Jeremy Zucker³³, Kristie Oxford³³, Jeremy Teuton³³, Ebru Kocakaya³⁴, Gökçe Yağmur Summak³⁴, Kristina Hanspers³⁵, Martina Kutmon^{36,37}, Susan Coort³⁶, Lars Eijssen^{36,38}, Friederike Ehrhart^{36,38}, D. A. B. Rex³⁹, Denise Slenter³⁶, Marvin Martens³⁶, Nhung Pham³⁶, Robin Haw⁴⁰, Bijay Jassal⁴⁰, Lisa Matthews⁴¹, Marija Orlic-Milacic⁴⁰, Andrea Senff Ribeiro^{40,42}, Karen Rothfels⁴⁰, Veronica Shamovsky⁴¹, Ralf Stephan⁴⁰, Cristoffer Sevilla⁴³, Thawfeek Varusai⁴³, Jean-Marie Ravel^{44,45}, Rupsha Fraser⁴⁶, Vera Ortseifen⁴⁷, Silvia Marchesi⁴⁸, Piotr Gawron^{1,49}, Ewa Smula¹, Laurent Heirendt¹, Venkata Satagopam¹, Guanming Wu⁵⁰, Anders Riutta³⁵, Martin Golebiewski⁵¹, Stuart Owen⁵², Carole Goble⁵², Xiaoming Hu⁵¹, Rupert W. Overall^{53,54}, Dieter Maier⁵⁵, Angela Bauch⁵⁵, Benjamin M. Gyori⁵⁶, John A. Bachman⁵⁶, Carlos Vega¹, Valentin Grouès¹, Miguel Vazquez¹⁶, Pablo Porras^{43,57}, Luana Licata⁵⁸, Marta Iannuccelli⁵⁸, Francesca Sacco⁵⁸, Anastasia Nesterova⁵⁹, Anton Yuryev⁵⁹, Anita de Waard⁶⁰, Denes Turei⁶¹, Augustin Luna^{62,63}, Ozgun Babur⁶⁴, Sylvain Soliman³, Alberto Valdeolivas⁶¹, Marina Esteban-Medina^{65,66}, Maria Peña-Chilet^{65,66,67}, Kinza Rian^{65,66}, Tomáš Helikar⁶⁸, Bhanwar Lal Puniya⁶⁸, Dezso Modos^{69,70}, Agatha Treveil^{69,70}, Marton Olbei^{69,70}, Bertrand De Meulder⁷¹, Aurélien Dugourd^{61,72}, Aurélien Naldi³, Vincent Noël^{4,5,6}, Laurence Calzone^{4,5,6}, Chris Sander^{62,63}, Emek Demir¹², Tamas Korcsmaros^{69,70}, Tom C. Freeman⁷³, Franck Augé²², Jacques S. Beckmann⁷⁴, Jan Hasenauer^{29,75}, Olaf Wolkenhauer¹³, Egon L. Wilighagen³⁶, Alexander R. Pico³⁵, Chris T. Evelo^{36,37}, Marc E. Gillespie^{40,76}, Lincoln D. Stein⁴⁰, Henning Hermjakob⁴³, Peter D'Eustachio⁴¹, Julio Saez-Rodriguez⁶¹, Joaquin Dopazo^{65,66,67,77}, Alfonso Valencia^{16,78}, Hiroaki Kitano^{79,80}, Emmanuel Barillot^{4,5,6}, Charles Auffray⁷¹, Rudi Balling¹, Reinhard Schneider¹, **and the COVID-19 Disease Map Community**⁸¹

1. Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
2. Department of Biology, Univ. Evry, University of Paris-Saclay, GenHotel, Genopole, 91025, Evry, France
3. Lifeware Group, Inria Saclay-Ile de France, Palaiseau 91120, France
4. Institut Curie, PSL Research University, Paris, France.
5. INSERM, U900, Paris, France.
6. MINES ParisTech, PSL Research University, Paris, France.
7. Integrative Bioinformatics, Inc., 346 Paul Ave, Mountain View, CA, USA
8. Institut Pasteur, HIV, Inflammation and Persistence Unit, Paris, France
9. Bio Sorbonne Paris Cité, Université de Paris, Paris, France
10. Inserm- Institut national de la santé et de la recherche médicale. Saint-Louis Hospital 1 avenue Claude Vellefaux Pavillon Bazin 75475 Paris
11. Institute of Experimental Genetics (IEG), Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany
12. Oregon Health & Sciences University; Department of Molecular and Medical Genetics; 3222 SW Research Drive, Portland, Oregon, U.S.A 97239
13. Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany
14. Department of Computer and Information Science, University of Konstanz, Konstanz, Germany
15. Monash University, Faculty of Information Technology, Department of Human-Centred Computing, Wellington Rd, Clayton VIC 3800, Australia
16. Barcelona Supercomputing Center (BSC), Barcelona, Spain
17. Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522
18. Sanyo-Onoda City University, Faculty of Pharmaceutical Sciences, University St.1-1-1, Yamaguchi, Japan 756-0884
19. Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, 72076 Tübingen, Germany
20. Department of Computer Science, University of Tübingen, 72076 Tübingen, Germany
21. German Center for Infection Research (DZIF), partner site Tübingen, Germany
22. Riga Technical University, Institute of Applied Computer Systems, 1 Kalku Street, LV-1658 Riga, Latvia
23. Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France
24. Dipartimento di Epidemiologia Ricerca Pre-Clinica e Diagnostica Avanzata, National Institute for Infectious Diseases 'Lazzaro Spallanzani' I.R.C.C.S., Rome, Italy
25. COVID 19 INMI Network Medicine for IDs Study Group, National Institute for Infectious Diseases 'Lazzaro Spallanzani' I.R.C.C.S., Rome, Italy
26. Bioinformatics Core Facility, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
27. The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG
28. Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany
29. Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany
30. Technische Universität München, Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, 85748 Garching, Germany
31. Department of Chemical and Petroleum Engineering, University of Pittsburgh
32. Department of Computational and Systems Biology, University of Pittsburgh
33. Pacific Northwest National Laboratory, 902 Battelle Boulevard, Richland, WA, US
34. Ankara University, Stem Cell Institute, Ceyhan Atif Kansu St. No: 169 06520 Cevizlidere, Ankara, Turkey
35. Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158, US
36. Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands
37. Maastricht Centre for Systems Biology (MaCSBio), Maastricht University, Maastricht, The Netherlands
38. Maastricht University Medical Centre, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
39. Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India
40. Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3

41. NYU Grossman School of Medicine, New York NY 10016, US
42. Universidade Federal do Paraná, Brasil
43. EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD
44. University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France
45. Laboratoire de génétique médicale, CHRU Nancy, Nancy, France
46. The University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ
47. Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615 Bielefeld, Germany
48. Department of Surgical Science, Uppsala University, Sweden
49. Poznan University of Technology, Institute of Computing Science, ul. Piotrowo 2, 60-965 Poznan, Poland
50. Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA
51. Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg, Germany
52. The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK
53. German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany
54. Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Fetscherstraße 105, 01307 Dresden, Germany
55. Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany
56. Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA, US
57. Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD
58. University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy
59. Elsevier, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103, US
60. Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465, US
61. Heidelberg University, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany
62. cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, US
63. Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, US
64. University of Massachusetts Boston, Computer Science Department, 100 William T. Morrissey Blvd, Boston, MA 02125, US
65. Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), Hospital Virgen del Rocío, Sevilla, 41013, Spain
66. Computational Systems Medicine group, Institute of Biomedicine of Seville (IBIS). Hospital Virgen del Rocío, Sevilla 41013, Spain
67. Bioinformatics in Rare Diseases (BiER). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocío, 41013, Sevilla, Spain
68. University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, US
69. Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, UK
70. Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, UK
71. European Institute for Systems Biology and Medicine (EISBM), Vourles, France
72. Institute of Experimental Medicine and Systems Biology, Faculty of Medicine, RWTH, Aachen University, Aachen, Germany
73. The Roslin Institute, University of Edinburgh EH25 9RG
74. University of Lausanne, Lausanne, Switzerland
75. Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany
76. St. John's University College of Pharmacy and Health Sciences, Queens, NY USA
77. FPS/ELIXIR-es, Hospital Virgen del Rocío, Sevilla, 42013, Spain
78. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
79. Systems Biology Institute, Tokyo Japan
80. Okinawa Institute of Science and Technology Graduate School
81. FAIRDOMHub: <https://fairdomhub.org/projects/190>

Abstract

We describe a large-scale community effort to build an open-access, interoperable, and computable repository of COVID-19 molecular mechanisms - the COVID-19 Disease Map. We discuss the tools, platforms, and guidelines necessary for the distributed development of its contents by a multi-faceted community of biocurators, domain experts, bioinformaticians, and computational biologists. We highlight the role of relevant databases and text mining approaches in enrichment and validation of the curated mechanisms. We describe the contents of the Map and their relevance to the molecular pathophysiology of COVID-19 and the analytical and computational modelling approaches that can be applied for mechanistic data interpretation and predictions. We conclude by demonstrating concrete applications of our work through several use cases and highlight new testable hypotheses.

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) already resulted in the infection of over 106 million people worldwide, of whom 2.3 million have died¹. The molecular pathophysiology that links SARS-CoV-2 infection to the clinical manifestations and course of COVID-19 is complex and spans multiple biological pathways, cell types and organs [1,2]. To gain insight into this network of molecular mechanisms we need knowledge collected from the scientific literature and bioinformatic databases, integrated using formal systems biology standards. A repository of such computable knowledge will support data analysis and predictive modelling.

With this goal in mind, we initiated a collaborative effort involving over 230 biocurators, domain experts, modellers and data analysts from 120 institutions in 30 countries to develop the COVID-19 Disease Map, an open-access collection of curated computational diagrams and models of molecular mechanisms implicated in the disease [3].

To this end, we aligned the biocuration efforts of the Disease Maps Community [4,5], Reactome [6], and WikiPathways [7] and developed common guidelines utilising standardised encoding and annotation schemes, based on community-developed systems biology standards [8–10], and persistent identifier repositories [11]. Moreover, we integrated relevant knowledge from public repositories [12–15] and text mining resources, providing a means to update and refine the contents of the Map. The fruit of these efforts was a series of pathway diagrams describing key events in the COVID-19 infectious cycle and host response.

¹ <https://covid19.who.int/>

This comprehensive diagrammatic description of disease mechanisms is machine-readable and computable. This allows us to develop novel bioinformatics workflows, creating executable networks for analysis and prediction. In this way, the Map is both human and machine-readable, lowering communication barriers between biocurators, domain experts, and computational biologists significantly. Computational modelling, data analysis, and their informed interpretation using the contents of the Map have the potential to identify molecular signatures of disease predisposition and development, and to suggest drug repositioning for improving current treatments.

The current COVID-19 Disease Map is a collection of 41 diagrams containing 1836 interactions between 5499 elements, supported by 617 publications and preprints. The summary of diagrams available in the COVID-19 Disease Map can be found online² in Supplementary Material 1. The Map is a constantly evolving resource, refined and updated by ongoing efforts of biocuration, sharing and analysis. Here, we report its current status.

In Section 2, we explain the set up of our community effort to construct the interoperable content of the resource, involving biocurators, domain experts and data analysts. In Section 3, we demonstrate that the scope of the biological maps in the resource reflects the state-of-the-art about the molecular biology of COVID-19. Next, we outline analytical workflows that can be used on the contents of the Map, including initial, preliminary outcomes of two such workflows, discussed in detail as use cases in Section 4. We conclude in Section 5 with an outlook to further development of the COVID-19 map and the utility of the entire resource in future efforts to build and apply disease-relevant computational repositories.

² https://covid.pages.uni.lu/map_contents

2. Building and sharing the interoperable content

The COVID-19 Disease Map project involves: (i) biocurators, (ii) domain experts, and (iii) analysts and modellers:

i. Biocurators develop a collection of systems biology diagrams focused on the molecular mechanisms of SARS-CoV-2.

ii. Domain experts refine the contents of the diagrams, supported by interactive visualisation and annotations.

iii. Analysts and modellers develop computational workflows to generate hypotheses and predictions about the mechanisms encoded in the diagrams.

All three groups have an essential role in the process of building the Map, by providing content, refining it, and defining its computational use. Figure 1 illustrates the ecosystem of the COVID-19 Disease Map Community, highlighting the roles of different participants, available format conversions, interoperable tools, and downstream uses. Information about the community members and their contributions is disseminated via the FAIRDOMHub [16], so that content distributed across different collections can be uniformly referenced.

2.1 Creating and accessing the diagrams

The biocurators of the COVID-19 Disease Map diagrams follow the guidelines developed by the Community, and specific workflows of WikiPathways [7] and Reactome [6]. The biocurators build literature-based systems biology diagrams, representing the molecular processes implicated in COVID-19 pathophysiology, their complex regulation and the phenotypic outcomes. These diagrams are the main building blocks of the Map, composed of biochemical reactions and interactions (altogether called interactions) taking place between different types of molecular entities in various cellular compartments. As multiple teams work on related topics, biocurators can provide an expert review across pathways and across platforms. This is possible, as all platforms offer intuitive visualisation, interpretation, and analysis of pathway knowledge to support basic and clinical research, genome analysis, modelling, systems biology, and education. Table 1 lists information about the created content. For more details see Supplementary Material 1.




Figure 1: The ecosystem of the COVID-19 Disease Map Community. The main groups of COVID-19 Disease Map Community are biocurators, domain experts, analysts, and modellers; communicating to refine, interpret and apply COVID-19 Disease Map diagrams. These diagrams are created and maintained by biocurators, following pathway database workflows or standalone diagram editors, and reviewed by domain experts. The content is shared via pathway databases or a GitLab repository; all can be enriched by integrated resources of text mining and interaction databases. The COVID-19 Disease Map diagrams are available in several layout-aware systems biology formats and integrated with external repositories, allowing a range of computational analyses, including network analysis and Boolean, kinetic or multiscale simulations.

Both interactions and interacting entities are annotated following a uniform, persistent identification scheme, using either MIRIAM or Identifiers.org [17], and the guidelines for annotations of computational models [18]. Viral protein interactions are explicitly annotated with their taxonomy identifiers to highlight findings from strains other than SARS-CoV-2. Moreover, tools like ModelPolisher [19], SBMLsqueezer [20] or MEMOTE³ help to automatically complement the annotations in the SBML format and validate the model (see also Supplementary Material 2).

³ <https://memote.io>

Table 1. COVID-19 Disease Map contents. The table summarises biocuration resources and content of the Map across three main parts of the repository. All diagrams are listed in Supplementary Table 1. Online available at https://covid.pages.uni.lu/map_contents.

	Source		
	Individual diagrams	Reactome	WikiPathways
Diagram contents	21 diagrams 1334 interactions 4272 molecular entities 397 publications	2 diagrams 101 interactions 489 molecular entities 227 publications	19 diagrams 401 interactions 738 molecular entities 61 publications
Access	Gitlab git-r3lab.uni.lu/covid/models	SARS-CoV-1 and SARS-CoV-2 infections collection reactome.org/PathwayBrowser/#/R-HSA-9679506	COVID pathways collection covid.wikipathways.org
Exploration	The MINERVA Platform [21] covid19map.elixir-luxembourg.org Guide: covid.pages.uni.lu/minerva-guide	Native web interface Guide: covid.pages.uni.lu/reactome-guide	Native web interface Guide: covid.pages.uni.lu/wikipathways-guide
Biocuration guidelines	Community ⁴	Community ⁵ Platform-specific ⁵	Community ⁶ Platform-specific ⁶
Diagram Editors	CellDesigner ⁷ Newt ⁸ SBGN-ED [22] yEd+ySBGN ⁹	Reactome pathway editor ⁵	PathVisio [23]
Formats	CellDesigner SBML [24] SBGNML [25,26]	Internal, SBML and SBGNML compliant	GPML [23]

2.2 Enrichment using knowledge from databases and text mining

The knowledge on COVID-19 mechanisms is rapidly evolving, as demonstrated by the rapid growth of the COVID-19 Open Research Dataset (CORD-19) dataset, a source of scientific manuscripts and metadata on COVID-19 and related coronavirus research [27]. CORD-19 currently contains over 130,000 articles and preprints, over four times more than when it

⁴ https://docs.google.com/document/d/1DFfjZe2xjXrKMHorp_-7hlqWoNVSmx6sIzAaRzXgtQs

⁵ <https://reactome.org/community/training>

⁶ https://www.wikipathways.org/index.php/Help:Editing_Pathways

⁷ <http://celldesigner.org>

⁸ <https://newteditor.org>

⁹ <https://github.com/sbgn/ySBGN>

was introduced¹⁰. In such a quickly evolving environment, biocuration efforts need to be supported by repositories of structured knowledge about molecular mechanisms relevant for COVID-19, like molecular interaction databases, or text mining resources. Contents of such repositories may suggest improvements in the existing COVID-19 Disease Map diagrams, or establish a starting point for developing new pathways (see Section “Biocuration of database and text mining content”).

Interaction and pathway databases

Interaction and pathway databases contain structured and annotated information on protein interactions or causal relationships, while interaction databases focus on pairs of molecules, offering broad coverage of literature-reported findings, pathway databases describe biochemical processes and their regulations, supported by diagrams. Both types of resources are valuable inputs for COVID-19 Disease Map biocurators, given the comparability of identifiers used for molecular annotations, and the reference to publications used for defining an interaction or building a pathway. Table 2 summarises open-access resources supporting the biocuration of the Map. See Supplementary Materials [tools] for their detailed description.

Table 2. Resources supporting biocuration of the COVID-19 Disease Map. They include (i) collections of COVID-19 interactions, published by the IMEx Consortium [13] and SIGNOR 2.0 [14], (ii) a non-COVID interaction database OmniPath [12] and (iii) the Elsevier Pathway Collection, a manually reconstructed open-access dataset of annotated pathway diagrams for COVID-19¹¹.

Resource	Type	Manually curated	Directed	Layout	COVID-19 specific
IMEx Consortium database [28]	Interaction	Yes	No	No	Yes ¹² [13]
SIGNOR 2.0 database [14]	Interaction	Yes	Yes	Yes	Yes ¹³
OmniPath database [12]	Interaction	No	Yes	No	No
Elsevier Pathway Collection ¹⁴	Pathway	Yes	Yes	Yes	Yes ⁹

¹⁰ <https://www.semanticscholar.org/cord19/download> (accessed on 20.10.2020)

¹¹ <https://data.mendeley.com/datasets/h9vs5s8fz2/draft?a=f40961bb-9798-4fd1-8025-e2a3ba47b02e>

¹² [https://www.ebi.ac.uk/intact/imex/main.xhtml?query=annot:"dataset:coronavirus"](https://www.ebi.ac.uk/intact/imex/main.xhtml?query=annot:)

¹³ <https://signor.uniroma2.it/covid/>

¹⁴ <https://pathwaystudio.com>

Text mining resources

Text-mining approaches can help to sieve through such rapidly expanding literature with natural language processing (NLP) algorithms based on semantic modelling, ontologies, and linguistic analysis to automatically extract and annotate relevant sentences, biomolecules, and their interactions. This scope was recently extended to pathway figure mining, decoding pathway figures into their computable representations [29]. Altogether, these automated workflows lead to the construction of knowledge graphs: semantic networks incorporating ontology concepts, unique biomolecule references, and their interactions extracted from abstracts or full-text documents [30].

The COVID-19 Disease Map Project integrates open-access text mining resources, INDRA [31], BioKB¹⁵, AILANI COVID-19¹⁶, and PathwayStudio¹⁴. All platforms offer keyword-based search allowing interactive exploration. Additionally, the Map benefits from an extensive protein-protein interaction network (PPI)¹⁷ generated with a custom text-mining pipeline using OpenNLP¹⁸ and GNormPlus [32]. This pipeline was applied to the COVID-19 dataset and the collection of MEDLINE abstracts associated with the genes in the SARS-CoV-2 PPI network [33] using the Entrez Gene Reference-Into-Function (GeneRIF). For detailed descriptions of the resources, see Supplementary Material 3.

Biocuration using database and text mining content

Molecular interactions from databases and knowledge graphs from text mining resources discussed above (from now on called altogether ‘knowledge graphs’) have a broad coverage at the cost of depth of mechanistic representation. This content can be used by the biocurators to build and update the systems biology focused diagrams. Biocurators can use this content in three main ways: by visual exploration, by programmatic comparison, and by direct incorporation of the content.

First, the biocurators can visually explore the contents of the knowledge graphs using available search interfaces to locate new knowledge and encode it in the diagrams. Moreover, solutions like COVIDminer project¹⁹, PathwayStudio¹⁴ and AILANI offer a visual representation of a group of interactions for a better understanding of their biological context, allowing search by interactions, rather than just isolated keywords. Finally, INDRA and AILANI offer assistant bots that respond to natural language queries and return meaningful answers extracted from knowledge graphs.

¹⁵ <https://biokb.lcsb.uni.lu>

¹⁶ <https://ailani.ai>

¹⁷ <https://git-r3lab.uni.lu/covid/models/-/tree/master/Resources/Text%20mining>

¹⁸ <https://opennlp.apache.org>

¹⁹ <https://rupertoverall.net/covidminer>

Second, programmatic access and reproducible exploration of the knowledge graphs is possible via data endpoints: SPARQL for BioKB and Application Programming Interfaces for INDRA, AILANI, and Pathway Studio. Users can programmatically submit keyword queries and retrieve functions, interactions, pathways, or drugs associated with submitted gene lists. This way, otherwise time-consuming tasks like an assessment of completeness of a given diagram, or search for new literature evidence, can be automated to a large extent.

Finally, biocurators can directly incorporate the content of knowledge graphs into SBML format using BioKC [34]. Additionally, the contents of the Elsevier COVID-19 Pathway Collection can be translated to SBGNML²⁰ preserving the layout of the diagrams. The SBGNML content can then be converted into other diagram formats used by biocurators (see Section 2.3 below).

2.3 Interoperability of the diagrams and annotations

The biocuration of the COVID-19 Disease Map is distributed across multiple teams, using varying tools and associated systems biology representations. This requires a common approach to annotations of evidence, biochemical reactions, molecular entities and their interactions. Moreover, interoperability of layout-aware formats is needed for comparison and integration of the diagrams in the Map.

Layout-aware formats for molecular mechanisms

The COVID-19 Disease Map diagrams are encoded in one of three layout-aware formats for standardised representation of molecular interactions: SBML²¹ [35–37], SBGNML [26], and GPML [23]. These XML-based formats focus to a varying degree on user-friendly graphical representation, standardised visualisation, and support of computational workflows. For the detailed description of the formats, see Supplementary Material 1.

Each of these three languages has a different focus: SBML emphasises standardised representation of the data model underlying molecular interactions, SBGNML provides a standardised graphical representation of molecular processes, while GPML allows for a partially standardised representation of uncertain biological knowledge. Nevertheless, all three formats are centred around molecular interactions, provide a constrained vocabulary to encode element and interaction types, encode layout of their diagrams and support stable identifiers for diagram components. These shared properties, supported by a common ontology²² [38], allow cross-format mapping and enable translation of key properties between the formats. Therefore, when developing the contents of the Map, biocurators use the tools they are familiar with, facilitating this distributed task.

²⁰ <https://github.com/golovatenkop/rnef2sbgm>

²¹ here, SBML stands for two formats: CellDesigner SBML and SBML with *layout* and *render* packages

²² <http://www.ebi.ac.uk/sbo/main/>

Format interoperability

The COVID-19 Disease Map Community ecosystem of tools and resources (see Figure 1) ensures interoperability between the three layout-aware formats for molecular mechanisms: SBML, SBGNML, and GPML. Essential elements of this setup are tools capable of providing cross-format translation functionality [39,40] and supporting harmonised visualisation processing. Another essential translation interface is a representation of Reactome pathways in WikiPathways GPML [41] and SBML. The SBML export of Reactome content has been optimised in the context of this project and facilitates integration with the other COVID-19 Disease Map software components.

The contents of the COVID-19 Disease Map diagrams can be directly transformed into inputs of computational pipelines and data repositories. Besides the direct use of SBML format in kinetic simulations, CellDesigner SBML files can be transformed into SBML qual [42] using CaSQ [43], enabling Boolean modelling-based simulations (see also Supplementary Material 3). CaSQ preserves annotations and layout information for transparency and reusability of the models. In parallel, CaSQ converts the diagrams to the SIF format²³, supporting pathway modelling workflows using simplified interaction networks. Notably, the GitLab repository features an automated translation of stable versions of diagrams into SBML qual. Finally, translation of the diagrams into XGMML format (the eXtensible Graph Markup and Modelling Language) using Cytoscape [44] or GINSim [45] allows for network analysis and interoperability with molecular interaction repositories [46].

3. Structure and scope of the COVID-19 Disease Map

The COVID-19 Disease Map is the product of a large-scale community effort. It was built bottom-up, exploiting a rich bioinformatics framework, on a skeleton provided from previous extensive studies of other coronaviruses [47] and contextualised with data emerging from studies of SARS-CoV-2 [33]. We developed and applied analytical and modelling workflows, using text mining approaches and contents of interaction databases, to propose preliminary insights into COVID-19 molecular mechanisms. The Map continues to grow, following emerging scientific literature. Its content is currently centred on molecular processes involved in SARS-CoV-2 entry and replication, and host-virus interactions. As scientific evidence of host susceptibility, immune response, cell and organ specificity emerge, these will be incorporated into future versions of the Map (Figure 2).

²³ <http://www.cbmc.it/fastcent/doc/SifFormat.htm>




Figure 2: The structure and content of the COVID-19 Disease Map. The areas of focus of the COVID-19 Map biocuration.

While the interactions of SARS-CoV-2 with various host cell types are vital determinants of COVID-19 pathology [2,48–52], the current Map represents an infection of a generic host cell. Several pathways included in the COVID-19 Map are shared between different cell types, for example the IFN-1 pathway found in dendritic and epithelial cells, and in alveolar macrophages [53–57]. Continued annotations of emerging expression data sets and other sources of information will allow the construction of cell-specific versions of the Map to provide an integrated view of the effects of SARS-CoV-2 on the human organism.

SARS-CoV-2 infection and COVID-19 progression are sequential events that start with viral attachment and entry (Figure 3). These events involve various dynamic processes and different time scales that are not captured in static representations of pathways. Correlation of symptoms and potential drugs suggested to date helps downstream data exploration and drug target interpretation in the context of therapeutic interventions.




Figure 3: Overview of the Map in the context of COVID-19 progression. Pathways and cell types involved in COVID-19, including some of the most common clinical manifestations and medical management from the moment of infection to disease resolution. The distribution of the elements is for illustrative reference and does not necessarily indicate either a unique/static interplay of these elements or an unvarying progression. For the literature on clinical manifestations see [58–64].

Supplementary Material 1 summarises the contents of the COVID-19 Disease Map diagrams, their central platform of reference. The online version of the table is continuously updated to reflect the evolving content of the COVID-19 Disease Map²⁴.

3.1 Contents of the Map

Virus replication cycle

The virus replication cycle includes binding of the spike surface glycoprotein (S) to angiotensin-converting enzyme 2 (ACE2) mediated by TMPRSS2 [65–68], and other receptors [69,70]. Viral entry occurs either by direct fusion of the virion with the cell membranes or by endocytosis [67,71,72] of the virion membrane, and the subsequent injection of the nucleocapsid into the cytoplasm. Within the host cell, the Map depicts how SARS-CoV-2 hijacks the rough endoplasmic reticulum (RER)-linked host translational machinery for its replication [47,73–78]. The RER-attached translation machinery

²⁴ https://covid.pages.uni.lu/map_contents

produces structural proteins, which together with the newly generated viral RNA are assembled into new virions and released to the extracellular space via smooth-walled vesicles [47,73] or hijacked lysosomes [79].

Viral subversion of host defence

Endoplasmic reticulum (ER) stress is a consequence of the production of large amounts of viral proteins that create an overload of unfolded proteins [80–82]. The mechanisms of the unfolded protein response (UPR) [83] include the mitigation of the misfolded protein load by increased protein degradation and reduced protein synthesis [84–86]. Malfunctioning proteins and damaged organelles are degraded through the ubiquitin-proteasome system (UPS) and autophagy [87–91]. SARS-CoV-2 may perturb the process of UPS-based protein degradation via the interaction of the Orf10 virus protein with the Cul2 ubiquitin ligase complex and its potential substrates [33,92]. Its involvement in autophagy is less documented [93,94].

This increased burden of misfolded proteins due to viral replication and subversion of mitigation mechanisms may trigger programmed cell death (apoptosis). The Map encodes major signalling pathways triggering this final form of cellular defence against viral replication [95–97]. Many viruses block or delay cell death by expressing anti-apoptotic proteins to maximise the production of viral progeny [98,99], or induce it in selected cell types [97,100–105].

Host integrative stress response

SARS-CoV-2 infection damages the epithelium and the pulmonary capillary vascular endothelium [106,107], causing impaired respiratory capacity and leading to acute respiratory distress syndrome (ARDS) in severe forms of COVID-19 [60,108,109]. The release of pro-inflammatory cytokines and hyperinflammation are known complications, causing further widespread damage [110–113]. Coagulation disturbances and thrombosis are associated with severe cases, but unique specific mechanisms have not been described yet [63,114–116]. Nevertheless, it was shown that SARS-CoV-2 disrupts the coagulation cascade and causes renin-angiotensin system (RAS) imbalance [117,118].

ACE2, used by SARS-CoV-2 for host cell entry, is a regulator of RAS and is widely expressed in the affected organs. The diagrams in the repository describe how ACE2-converted angiotensins trigger the counter-regulatory arms of RAS, and the downstream signalling via AGTR1, regulating the coagulation cascade [119–121].

Host immune response

The innate immune system detects specific pathogen-associated molecular patterns, through Pattern Recognition Receptors (PRRs), that recognise viral RNA in the endosome during endocytosis, or in the cytoplasm during virus replication. The PRRs activate associated transcription factors promoting the production of antiviral proteins like interferon-alpha, beta and lambda [47,54,55,57,122–127]. SARS-CoV-2 impairs this mechanism [48], but the exact components are yet to be elucidated [128–134]. The Map includes both the virus recognition process and the viral evasion mechanisms. It provides the connection between virus entry, its replication cycle, and the effector pathways of pro-inflammatory cytokines, especially of the interferon type I cascade [2,47,57,130,135–141].

Key metabolic pathways modulate the availability of nutrients and critical metabolites of the immune microenvironment [142]. They are a target of infectious entities that reprogram host metabolism to create favourable conditions for their reproduction [143]. The Map encodes several immunometabolic pathways and provides detailed information about the way SARS-CoV-2 proteins interact with them. The metabolic pathways include heme catabolism [144–146] and its downstream target, the NLRP3 inflammasome [147–152], both affected by SARS-CoV and SARS-CoV-2 proteins [33,153–157], tryptophan-kynurenine metabolism, governing the response to inflammatory cytokines [158–162], and nicotinamide and purine metabolism [163–166] targeted by SARS-CoV-2 [33]. Finally, we represent the pyrimidine synthesis pathway, tightly linked to purine metabolism, affecting viral DNA and RNA synthesis [167–169].

3.2 Exploration of the networked knowledge

The pathway diagrams of the COVID-19 Map are constructed by community curators. Their assembly into a repository with standard encoding and annotation, linked to interaction and text mining databases (see Section 2.2) supports exploration to identify crosstalks and functional overlaps across pathways. These analyses allow us to fill gaps in our understanding of COVID-19 mechanisms and generate new testable hypotheses (see Supplementary Material 4). Below, we discuss three examples of our exploration of the networked knowledge in the Map, illustrated in Figure 4.




Figure 4: Exploration of the existing and new crosstalks between the diagrams of the COVID-19 Disease Map. The network structure of the diagrams and their interactions based on existing crosstalk (shared elements), new crosstalks and new regulators. A) Existing crosstalks between individual diagrams of IFN-I and RELA-related mechanisms; B) New crosstalks between pathway groups, and C) Novel regulators of existing diagrams as suggested by text mining and interaction databases. Colour code: green - pathways or pathway groups, blue - proteins with two neighbors, yellow - proteins with three or four, red - proteins with five or more. See Supplementary Material 4 for details.

Existing crosstalks between COVID 19 Disease Map diagrams

First, the existing pathway crosstalks emerge when entities are matched between different diagrams (Figure 4A). For instance, they link different pathways involved in type I IFN (IFN-1) signalling. Responses to RNA viruses and pathogen-associated molecular patterns (PAMPs) share common pathways, involving RIG-I/Mda-5, TBK1/IKKE and TLR signalling, leading to the production of IFN-1s, especially IFN-beta [170,171] and IFN-alpha [122]. Downstream, IFN-1 activates Tyk2 and Jak1 protein tyrosine kinases, causing STAT1:STAT2:IRF9 (ISGF3) complex formation to promote the transcription of IFN-stimulated genes (ISGs). Importantly, TBK1 also phosphorylates IKBA, an NF- κ B

inhibitor, for proteasomal degradation in crosstalk with the UPS pathway, allowing free NF- κ B and IRF3 to co-activate ISGs [172]. Another TBK1 activator, STING, links IFN signalling with pyrimidine metabolism.

SARS-CoV-2 M protein affects these IFN responses by inhibiting the RIG-I:MAVS:TRAF3 complex and TBK1, preventing IRF3 phosphorylation, nuclear translocation, and activation [173]. In severe COVID-19 cases, elevated NF- κ B activation, associated with impaired IFN-1 [54] may be a host attempt to compensate for the lack of IFN-1 activation [174], leading to NF- κ B hyperactivation and release of pro-inflammatory cytokines. Moreover, SARS-CoV-1 viral papain-like-proteases, contained within the nsp3 and nsp16 proteins, inhibit STING and its downstream IFN secretion [175]. Defective responses involving these pathways and other regulatory factors may impair the IFN response against SARS-CoV-2, and explain persistent blood viral load and an exacerbated inflammatory response in COVID-19 patients [54].

New crosstalks from interaction and text mining datasets

New relationships emerging from associated interaction and text mining databases (see Section 2.2) suggest new pathway crosstalks (see Figure 4B). One of these is the interaction of ER stress and the immune pathways, as PPP1R15A regulates the expression of TNF and the translational inhibition of both IFN-1 and IL-6 [176]. This finding coincides with the proposed interaction of pathways responsible for protein degradation and viral detection, as SQSTM1, an autophagy receptor and NF κ B1 regulator, controls the activity of cGAS, a double-stranded DNA detector [177,178]. Another association discovered in text mining data is ADAM17 and TNF release from the immune cells in response to ACE2-S protein interaction with SARS-CoV-1 [179], potentially increasing the risk of COVID-19 infection [180]. This new interaction connects diagrams of the i) “Viral replication cycle” via ACE2-S protein interactions, ii) “Viral subversion of host defence mechanisms” via ER stress, iii) “Host integrative stress response” via the renin-angiotensin system and iv) “Host innate immune response” via pathways implicating TNF signalling.

Novel regulators of key pathway proteins

Finally, using interaction and text mining databases, we can identify potential novel regulators of proteins in the Map (see Figure 4C). These proteins take no part in the current version of the Map but interact with molecules already represented in at least one of the diagrams. An example of such a novel regulator is NFE2L2, which controls the activity of HMOX1 in the context of viral infection [181,182]. In turn, HMOX1 controls immunomodulatory heme metabolism [144,145] and mechanisms of viral replication [183] and is a target of SARS-CoV-2 Orf3a protein [157,183]. The suggested NFE2L2-HMOX1 interaction is supported by the literature reports of NFE2L2 importance in COVID-19

cardiovascular complications due to crosstalk with the renin-angiotensin signalling pathway [184] and potential interactions with viral entry mechanisms [185]. Interestingly, the modulation of the NFE2L2-HMOX1 axis was already proposed as a therapeutic measure [186], making it an interesting extension of the COVID-19 Disease Map.

3.3 Biocuration roadmap

COVID-19 Disease Map pathways span a range of currently known host-cell virus interactions and mechanisms. Nevertheless, certain aspects of the disease are not represented in detail, particularly cell-type-specific immune response, and susceptibility features. Their mechanistic description is of great importance, as suggested by clinical reports on the involvement of these pathways in the molecular pathophysiology of the disease. The mechanisms outlined below will be the next targets in our curation roadmap.

Cell type-specific immune response

COVID-19 causes serious disbalance in multiple populations of immune cells, including peripheral CD4+ and CD8+ cytotoxic T lymphocytes, B cells and NK cells [111,162,187–190]. This may be the result of functional exhaustion due to SARS-CoV-2 S protein and excessive pro-inflammatory cytokine response [188,191], promoted by an abnormal increase of the Th17:Treg cell ratio [192]. Moreover, the ratio of naive-to-memory helper T-cells increases while the level of T regulatory cells decreases in severe cases [193]. Pulmonary recruitment of lymphocytes into the airways, including Th17 and cytotoxic CD8+ T-cells [194], may explain this imbalance and the increased neutrophil-lymphocyte ratio in peripheral blood [187,195,196]. To address this aspect of the disease we plan to implement cell type representations of different populations, and encode their cell surface receptors and transition mechanisms. With the help of single-cell omics profiling, we plan to adapt these to reflect COVID-19 specificity.

Susceptibility features of the host

SARS-CoV-2 infection is associated with increased morbidity and mortality in individuals with underlying medical conditions, chronic diseases or a compromised immune system [197–200]. Groups at risk are men, pregnant and postpartum women, and individuals with high occupational viral exposure [201–203]. Other susceptibility factors include the ABO blood groups [204–211] and respiratory conditions [212–217].

Importantly, age is one of the key aspects contributing to the severity of the disease [199,218]. Age-related elevated levels of inflammation [218–221], immunosenescence and cellular stress of ageing cells [108,199,218,222,223] may contribute to the risk. In contrast, children are generally less likely to develop severe disease [224,225], with the exception of

infants [108,226–228]. However, some previously healthy children and adolescents can develop a multisystem inflammatory syndrome following SARS-CoV-2 infection [229–233].

Finally, several genetic factors have been proposed and identified to influence susceptibility and severity, including the ACE2 gene, HLA locus, errors influencing type I IFN production, TLR pathways, myeloid compartments, as well as cytokine polymorphisms [207,234–241].

Connecting the susceptibility features to specific molecular mechanisms will allow us to better understand the contributing factors. These features can be directly incorporated as elements of relevant diagrams. Another possibility is connecting the diagrams of the Map to clinical and phenotypic data following big data workflows as demonstrated in other settings [3,242]. This can lead to a series of testable hypotheses, including the role of lipidomic reprogramming [243,244] or of vitamin D [245–247] in modifying the severity of the disease. Another testable hypothesis is that the immune phenotype associated with asthma inhibits pro-inflammatory cytokine production and modifies gene expression in the airway epithelium, protecting against severe COVID-19 [216,217,248].

4. Bioinformatics analysis and computational modelling roadmap for hypothesis generation

To understand complex and often indirect dependencies between different pathways and molecules, we need to combine computational and data-driven analyses. Standardised representation and programmatic access to the contents of the COVID-19 Disease Map support reproducible analytical and modelling workflows. Here, we discuss the range of possible approaches and demonstrate preliminary results, focusing on interoperability, reproducibility, and applicability of the methods and tools.

4.1 Data integration and network analysis

Visualisation of omics datasets can help contextualise the Map with experimental data, creating data-specific blueprints. They can highlight parts of the Map that are active in one condition versus another. Combining information contained in multiple omics platforms can make patient stratification more powerful, by reducing the number of samples needed or by augmenting the precision of the patient groups [249,250]. Approaches that integrate multiple data types without the accompanying mechanistic diagrams [251–253] produce patient groupings that are difficult to interpret. In turn, classical pathway analyses often produce long lists mixing generic and cell-specific pathways, making it challenging to pinpoint relevant information. Using disease maps to interpret omics-based clusters addresses the issues related to contextualised visual data analytics.

Footprint based analysis

Footprints are signatures of a molecular regulator determined by the expression levels of its targets [254]. Combining multiple omics readouts and multiple measurements can increase the robustness of such signatures. Nevertheless, an essential component is the mechanistic description of the targets of a given regulator, allowing computation of its footprint. With available SARS-CoV-2 related omics and interaction datasets [255], it is possible to infer which TFs and signalling pathways are affected upon infection [256]. Combining the COVID-19 Disease map regulatory interactions with curated collections of TF-target interactions like DoRothEA [257] will provide a contextualised evaluation of the effect of SARS-CoV-2 infection at the TF level.

Virus–host interactome

The virus–host interactome is a network of viral-human protein-protein interactions (PPIs) that can help to understand the mechanisms of viral diseases [33,258–260]. It can be expanded by merging virus-host PPI data with human PPI and protein data [261] to discover clusters of interactions indicating human mechanisms and pathways affected by the virus [262]. These clusters can be interpreted at the mechanistic level by visual exploration of COVID-19 Disease Map diagrams. In addition, these clusters can potentially reveal additional pathways to add to the COVID-19 Disease Map (e.g. E protein interactions or TGF beta diagrams) or suggest new interactions to introduce into the existing diagrams.

4.2 Mechanistic and dynamic computational modelling

Computational modelling is a powerful approach that enables *in silico* experiments, produces testable hypotheses, helps elucidate regulation and, finally, can suggest via predictions novel therapeutic targets and candidates for drug repurposing.

Mechanistic pathway modelling

Molecular interactions of a given pathway can be coupled with its endpoint and contextualised using omics datasets. For instance, HiPathia uses transcriptomic or genomic data to estimate the functional profiles of a pathway in relation to their endpoints of interest [263,264]. Such mechanistic modelling can be used to predict the effect of interventions,, for example effects of drugs on their targets [265]. HiPathia integrates directly with the diagrams of the COVID-19 Map using the SIF format provided by CaSQ (see Section 2.3), as well as with the associated interaction databases (see Section 2.2). The drawback of such approaches is their computational complexity, limiting the size of the diagrams they can process. Large-scale mechanistic pathway modelling requires their transformation into causal networks. CARNIVAL [266] combines the causal representation of networks [12] with transcriptomics, (phospho)proteomics, or metabolomics data [254]

to contextualise cellular networks and extract mechanistic hypotheses. The algorithm identifies a set of coherent causal links connecting upstream drivers such as stimulations or mutations to downstream changes in transcription factor activities.

Discrete computational modelling

Discrete modelling allows analysis of the dynamics of molecular networks to understand their complexity under disease-related perturbations. COVID-19 Disease Map diagrams, translated to SBML qual using CaSQ (see Section 2.3), can be directly imported by tools like Cell Collective [267] or GINsim [45] for analysis. Cell Collective is an online modelling platform²⁵ that provides features for real-time simulations and analysis of complex signalling networks. References and layout are used for model visualisation, supporting the interpretation of the results. In turn, GINsim provides a range of analysis methods, including identification of the states of convergence of a given model (attractors). Model reduction functionality can also be employed to facilitate the analysis of large-scale models.

Multiscale and stochastic computational modelling

Viral infection and immune response are processes that span many scales, from molecular interactions to multicellular behaviour. Modelling of such complex scenarios requires a multiscale computational architecture, where single cell models run in parallel to capture behaviour of heterogeneous cell populations and their intercellular communications. Multiscale agent-based models offer such architecture, and can simulate processes at different time scales, e.g. diffusion, cell mechanics, cell cycle, or signal transduction [268,269]. An example of such approach is PhysiBoSS [270], which combines the computational framework of PhysiCell [271] with MaBoSS [272], a tool for stochastic simulations of logical models to study of transient effects and perturbations [273]. Implementing detailed COVID-19 signalling models in the PhysiBoSS framework may help to better understand complex dynamics of interactions between immune system components and the host cell.

4.3 Case study: RNA-Seq-based analysis of transcription factor activity

We measured the effect of COVID-19 at the transcription factor (TF) activity level by applying VIPER [274] combined with DoRothEA regulons [257] on RNA-seq datasets of the SARS-CoV-2 infected Calu-3 cell line [126]. Then, we mapped the TFs normalised enrichment score (NES) on the *Interferon type I signalling pathway* diagram of the COVID-19 Disease Map using the SIF files generated by CaSQ (see Section 2.3). As highlighted in Figure 4, our manually curated pathway included some of the most active TFs after SARS-CoV-2 infection, such as STAT1, STAT2, IRF9 and NFKB1. These genes are

²⁵ <https://cellcollective.org>

well known to be involved in cytokine signalling and antiviral responses [275,276]. Interestingly, they are located downstream of various viral proteins (*E*, *S*, *Nsp1*, *Orf7a* and *Orf3a*) and members of the MAPK pathway (*MAPK8*, *MAPK14* and *MAP3K7*). SARS-CoV-2 infection is known to promote MAPK activation, which mediates the cellular response to pathogenic infection and promotes the production of pro-inflammatory cytokines [255]. These conclusions can be used to investigate response of the human cells to SARS-CoV-2 infection.




Figure 4: the Interferon type I signalling pathway diagram of the COVID-19 Disease Map integrated with TF activity derived from transcriptomics data after SARS-CoV-2 infection. A zoom was applied in the area containing the most active TFs (red nodes) after infection. Node shapes: host genes (rectangles), host molecular complex (octagons), viral proteins (V shape), drugs (diamonds) and phenotypes (triangles).

4.4 Case study: RNA-seq-based analysis of pathway signalling

The Hipathia [263] algorithm was used to calculate the level of activity of the subpathways from the COVID-19 Apoptosis diagram. We used a public RNA-seq dataset from human SARS-CoV-2 infected lung cells (GEO GSE147507). We treated the RNA-seq gene expression data with the Trimmed Mean of M values (TMM) normalisation [277], rescaled to range [0;1] for the calculation of the signal and normalised using quantile normalisation [278]. Using the normalised gene expression values we calculated the level of activation of the subpathways, then we used case/control contrast with a Wilcoxon test to assess differences in signalling activity between the two conditions.




Figure 5. Representation of the activation level of Apoptosis pathway in SARS-CoV-2 infected lung cell lines. Activation levels were calculated using transcriptional data from GSE147507 and the Hipathia mechanistic pathway analysis algorithm. Each node represents a gene (ellipse), a metabolite (circle) or a function (square). The pathway is composed of circuits from a receptor gene/metabolite to an effector gene/function, which take into account interactions simplified to inhibitions or activations (see Section 2.3, SIF format). Significantly deregulated circuits are highlighted by color arrows (red: activated in infected cells). The color of the node corresponds to the level of differential expression in SARS-CoV-2 infected cells vs normal lung cells. Blue: down-regulated elements, red: up-regulated elements, white: elements with no statistically significant differential expression.

Results of the Apoptosis pathway analysis can be seen in Figure 5 and Supplementary Material 5. The analysis shows an overactivation of several circuits (series of causally connected elements), specifically upstream of the effector protein BAX, led by the overexpression of the BAD protein, inhibiting BCL2-MCL1-BCL2L1 complex, which in turn inhibits BAX. Indeed, SARS-CoV-2 infection can invoke caspase8-induced apoptosis [279], where BAX together with the ripoptosome/caspase-8 complex, may act as a pro-inflammatory checkpoint [280]. This result is supported by studies in SARS-CoV-1, showing BAX overexpression following infection [104,281]. Overall, our findings recapitulate reported outcomes and suggest that with evolving contents of the COVID-19 Disease Map and new transcriptomic data becoming available, new mechanism-based hypotheses can be formulated.

4.5 Parallel efforts

There are parallel efforts towards modelling of COVID-19 mechanisms, providing a complementary source of information and their future integration will create an even broader toolset to tackle the pandemic.

The modified Edinburgh Pathway Notation (mEPN) [282] is a scheme for visual encoding of molecular processes in diagrams that also function as Petri nets, allowing activity simulations using the BioLayout tool [283]. The current mEPN COVID-19 model details the replication cycle of SARS-CoV-2, integrated with a range of host defence systems. Currently, models constructed in mEPN can be translated to SBGNML, but without the information related to their function as Petri nets.

The COVID-19 Disease Map can also support kinetic modelling to quantify the behaviour of pathways and evaluate the dynamic effects of perturbations. However, it is necessary to assign a kinetic equation or a rate law to every reaction in the diagram to be analysed. This process is challenging and requires support of tools like SBMLsqueezer [20] and reaction kinetics databases like SABIO-RK [284]. Nevertheless, the most critical factor is the availability of experimentally validated parameters that can be reliably applied in SARS-CoV-2 modelling scenarios.

5. Discussion

COVID-19 literature is growing at great speed, fueled by global research efforts to investigate the pathophysiology of SARS-CoV-2 infection and to better understand susceptibility factors and identify molecular targets of therapeutic intervention. We need to improve the use of this knowledge by tools and approaches to extract, formalise and integrate relevant information, and by application of analytical frameworks to generate testable hypotheses from systems level models.

The COVID-19 Disease Map is an open access knowledgebase and computational repository. On the one hand, it is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. On the other hand, it is a computational resource of curated content for graph-based analyses and disease modelling. It offers a shared mental map for understanding the dynamic nature of the disease at the molecular level and also its dynamic propagation at a systemic level. Thus, it provides a platform for a precise formulation of models, accurate data interpretation, monitoring of therapy, and potential for drug repositioning.

The COVID-19 Disease Map diagrams describe molecular mechanisms of COVID-19. These diagrams are grounded in the relevant published SARS-CoV-2 research, completed where necessary by mechanisms discovered in related beta-coronaviruses. With an unprecedented effort of community-driven biocuration, over forty diagrams with molecular resolution were constructed since March 2020, shared across three platforms.

This large community effort shows that expertise in biocuration, clear guidelines and text mining solutions can accelerate the passage from data generated in the published literature to a meaningful mechanistic representation of knowledge. This exercise in quick research data generation and knowledge accumulation may serve as a blueprint for a formalised and standardised streamline of well defined tasks.

Moreover, by developing reproducible analysis pipelines for the contents of the Map we promote early harmonisation of formats, support of standards, and transparency in all steps. Preliminary results of such efforts are illustrated in case studies above. Importantly, biocurators and domain experts participate in the analysis, helping to evaluate the outcomes and correct the curated content if necessary. This way, we improve the quality of the analysis and increase reliability of the models in generating useful predictions.

This approach to an emerging pandemic leveraged the capacity and expertise of an entire swath of the bioinformatics community, bringing them together to improve the way we build and share knowledge. By aligning our efforts, we strive to provide COVID-19 specific pathway models, synchronise content with similar resources and encourage discussion and feedback at every stage of the curation process.

The COVID-19 Disease Map community is open and expanding as more people with complementary expertise join forces. In the longer run, the COVID 19 Disease Map content will be used to facilitate the finding of robust signatures related to SARS-CoV-2 infection predisposition or response to various treatments, along with the prioritization of new potential drug targets or drug candidates. The project aims to provide the tools to deepen our understanding of the mechanisms driving the infection and help boost drug development supported by testable suggestions. Such an approach may help dealing with new waves of COVID-19 or similar pandemics in the long-term perspective.

Authors' contributions

M. Ostaszewski, A. Niarakis, A. Mazein and I. Kuperstein planned and coordinated the project;

R. Phair, A. Orta-Resendiz, J-M. Ravel, R. Fraser, V. Ortseifen and S. Marchesi advised the project as domain experts;

M. Ostaszewski, A. Niarakis, A. Mazein, I. Kuperstein, V. Singh, S.S. Aghamiri, M.L. Acencio, E. Glaab, A. Ruepp, G. Fobo, C. Montrone, B. Brauner, G. Frischman, L.C.M. Gomez, J. Sommers, M. Hoch, S. Gupta, J. Scheel, H. Borlinghaus, T. Czauderna, F. Schreiber, A. Montagud, M. Ponce de Leon, A. Funahashi, Y. Hiki, N. Hiroi, T.G. Yamada, A. Dräger, A. Renz, M. Naveez, Z. Bocskei, F. Messina, D. Börnigen, L. Fergusson, M. Conti, M. Rameil, V. Nakonecnij, J. Vanhoefer, L. Schmiester, M. Wang, E.E. Ackerman, J. Shoemaker, J. Zucker, K. Oxford, J. Teuton, E. Kocakaya, G.Y. Summak, K. Hanspers, M. Kutmon, S. Coort, L. Eijssen, F. Erhart, D.A.B. Rex, D. Slenter, M. Martens, N. Pham, R. Haw, B. Jassal, L. Matthews, M. Orlic-Milacic, A.S. Ribeiro, K. Rothfels, V. Shamovsky, R. Stephan, C. Sevilla and T. Varusai curated and reviewed the diagrams;

M. Ostaszewski, P. Gawron, E. Smula, L. Heirendt, V. Satagopam, G. Wu, A. Riutta, M. Golebiewski, S. Owen, C. Goble and X. Hu designed, developed and implemented key elements of the data sharing and communication infrastructure;

RW. Owen, D. Maier, A. Bauch, B.M. Gyori, J.A. Bauch, C. Vega, V. Groues, M. Vazquez, P. Porras, L. Licata, M. Ianucelli, F. Sacco, A. Nestorova, A. Yuryev, A. de Waard designed and developed the contents of interaction and pathway databases, and text mining platforms and their visualisation and interoperability functionalities;

A. Niarakis, D. Turei, A. Luna, O. Babur, S. Soliman, A. Valdeolivas, M. Esteban, M. Pena, K. Rian, T. Helikar, B.L. Puniya, D. Modos, A. Treveil, M. Olbei, B. De Meulder, A. Dugourd, A. Naldi, V. Noel, L. Calzone developed format interoperability, analysis and modelling workflows;

C. Sander, E. Demir, T. Korcsmaros, T. Freeman, F. Augé, J.S. Beckmann, J. Hasenauer, O. Wolkenhauer, E.L. Wilighagen, A.R. Pico, C.T. Evelo, M.E. Gillespie, L. Stein, H. Hermjakob, P. D'Eustachio, J. Saez-Rodriguez, J. Dopazo, A. Valencia, H. Kitano, E. Barillot, C. Auffray, R. Balling, R. Schneider defined the strategy and scope of the project and revised its progress;

M. Ostaszewski, A. Niarakis, A. Mazein and I. Kuperstein wrote the manuscript;

A. Orta-Resendiz, I. Kuperstein and A. Mazein designed the overview figures;

A. de Waard, P. D'Eustachio, J.S. Beckmann and L.D. Stein revised and contributed significantly to the structure of the manuscript;

All authors have revised, read and accepted the manuscript in its final form.

Acknowledgements

We would like to thank Andjela Tatarovic, architect, and Gina Crovetto, researcher in the field of cancer, for their help with the design of the top-level view diagrams. We would like to acknowledge the Responsible and Reproducible Research (R3) team of the Luxembourg Centre for Systems Biomedicine for supporting the project and providing necessary communication and data sharing resources. The work presented in this paper was carried out using the ELIXIR Luxembourg tools and services. EG acknowledges support from the Luxembourg National Research Fund (FNR) as part of the COVID-19 Fast-Track grant programme (COVID-19/2020-1/14715687/CovScreen).

Supplementary Materials

Supplementary Material 1: COVID-19 Disease Map diagrams

Supplementary Material 2: Biocuration platforms and formats

Supplementary Material 3: Description of bioinformatic resources

Supplementary Material 4: Exploration of crosstalks in the COVID-19 Disease Map diagrams

Supplementary Material 5: Results of the Hipathia analysis of the Apoptosis pathway

Bibliography

1. Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the Kidney: From Epidemiology to Clinical Practice. *J Clin Med*. 2020;9.
2. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell*. 2020;181:1016-1035.e19.
3. Ostaszewski M, Mazein A, Gillespie ME, Kuperstein I, Niarakis A, Hermjakob H, et al. COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. *Sci Data*. 2020;7:136.
4. Mazein A, Ostaszewski M, Kuperstein I, Watterson S, Le Novère N, Lefaudeux D, et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. *NPJ Syst Biol Appl*. 2018;4:21.
5. Ostaszewski M, Gebel S, Kuperstein I, Mazein A, Zinovyev A, Dogrusoz U, et al. Community-driven roadmap for integrated disease maps. *Brief Bioinform*. 2019;20:659–70.
6. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The Reactome Pathway Knowledgebase. *Nucleic Acids Res*. 2020;48:D498–503.
7. Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. *Nucleic*

Acids Res. 2018;46:D661–7.

8. Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, et al. The Systems Biology Graphical Notation. *Nat Biotechnol.* 2009;27:735–41.
9. Keating SM, Waltemath D, König M, Zhang F, Dräger A, Chaouiya C, et al. SBML Level 3: an extensible format for the exchange and reuse of biological models. *Mol Syst Biol.* 2020;16:e9110.
10. Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, et al. The BioPAX community standard for pathway data sharing. *Nat Biotechnol.* 2010;28:935–42.
11. Wimalaratne SM, Juty N, Kunze J, Janée G, McMurry JA, Beard N, et al. Uniform resolution of compact identifiers for biomedical data. *Sci Data.* 2018;5:180029.
12. Türei D, Korcsmáros T, Saez-Rodriguez J. OmniPath: guidelines and gateway for literature-curated signaling pathway resources. *Nat Methods.* 2016;13:966–7.
13. Perfetto L, Pastrello C, Del-Toro N, Duesbury M, Iannuccelli M, Kotlyar M, et al. The IMEx Coronavirus interactome: an evolving map of Coronaviridae-Host molecular interactions. *BioRxiv Prepr Serv Biol.* 2020;
14. Licata L, Lo Surdo P, Iannuccelli M, Palma A, Micarelli E, Perfetto L, et al. SIGNOR 2.0, the SIGNaling Network Open Resource 2.0: 2019 update. *Nucleic Acids Res.* 2020;48:D504–10.
15. Rodchenkov I, Babur O, Luna A, Aksoy BA, Wong JV, Fong D, et al. Pathway Commons 2019 Update: integration, analysis and exploration of pathway data. *Nucleic Acids Res.* 2020;48:D489–97.
16. Wolstencroft K, Krebs O, Snoep JL, Stanford NJ, Bacall F, Golebiewski M, et al. FAIRDOMHub: a repository and collaboration environment for sharing systems biology research. *Nucleic Acids Res.* 2017;45:D404–7.
17. Juty N, Le Novère N, Laibe C. Identifiers.org and MIRIAM Registry: community resources to provide persistent identification. *Nucleic Acids Res.* 2012;40:D580–586.
18. Niarakis A, Kuiper M, Ostaszewski M, Malik Sherif RS, Casals-Casas C, Thieffry D, et al. Setting the basis of best practices and standards for curation and annotation of logical models in biology-highlights of the [BC]2 2019 CoLoMoTo/SysMod Workshop. *Brief Bioinform.* 2020;
19. Römer M, Eichner J, Dräger A, Wrzodek C, Wrzodek F, Zell A. ZBIT Bioinformatics Toolbox: A Web-Platform for Systems Biology and Expression Data Analysis. *PloS One.* 2016;11:e0149263.
20. Dräger A, Zielinski DC, Keller R, Rall M, Eichner J, Palsson BO, et al. SBMLsqueezer 2: context-sensitive creation of kinetic equations in biochemical networks. *BMC Syst Biol.* 2015;9:68.
21. Gawron P, Ostaszewski M, Satagopam V, Gebel S, Mazein A, Kuzma M, et al. MINERVA-a platform for visualization and curation of molecular interaction networks. *NPJ Syst Biol Appl.* 2016;2:16020.
22. Czauderna T, Klukas C, Schreiber F. Editing, validating and translating of SBGN maps. *Bioinforma Oxf Engl.* 2010;26:2340–1.
23. Kutmon M, van Iersel MP, Bohler A, Kelder T, Nunes N, Pico AR, et al. PathVisio 3: an extendable pathway analysis toolbox. *PLoS Comput Biol.* 2015;11:e1004085.
24. Matsuoka Y, Funahashi A, Ghosh S, Kitano H. Modeling and simulation using CellDesigner. *Methods Mol Biol Clifton NJ.* 2014;1164:121–45.
25. van Iersel MP, Villéger AC, Czauderna T, Boyd SE, Bergmann FT, Luna A, et al. Software support for SBGN maps: SBGN-ML and LibSBGN. *Bioinforma Oxf Engl.* 2012;28:2016–21.

26. Bergmann FT, Czauderna T, Dogrusoz U, Rougny A, Dräger A, Touré V, et al. Systems biology graphical notation markup language (SBGNML) version 0.3. *J Integr Bioinforma.* 2020;17.
27. Lu Wang L, Lo K, Chandrasekhar Y, Reas R, Yang J, Eide D, et al. CORON-19: The Covid-19 Open Research Dataset. *ArXiv.* 2020;
28. Orchard S, Kerrien S, Abbani S, Aranda B, Bhate J, Bidwell S, et al. Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. *Nat Methods.* 2012;9:345–50.
29. Hanspers K, Riutta A, Kutmon M, Pico AR. 25 Years of Pathway Figures [Internet]. *Bioinformatics*; 2020 May. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.05.29.124503>
30. Bauch A, Pellet J, Schleicher T, Yu X, Gelemanović A, Cristella C, et al. Informing epidemic (research) responses in a timely fashion by knowledge management - a Zika virus use case [Internet]. *Pathology*; 2020 Apr. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.04.17.044743>
31. Gyori BM, Bachman JA, Subramanian K, Muhlich JL, Galescu L, Sorger PK. From word models to executable models of signaling networks using automated assembly. *Mol Syst Biol.* 2017;13:954.
32. Wei C-H, Kao H-Y, Lu Z. GNormPlus: An Integrative Approach for Tagging Genes, Gene Families, and Protein Domains. *BioMed Res Int.* 2015;2015:1–7.
33. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature.* 2020;583:459–68.
34. Vega C, Grouès V, Ostaszewski M, Schneider R, Satagopam V. BioKC: a collaborative platform for systems biology model curation and annotation [Internet]. *Systems Biology*; 2020 Oct. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.10.01.322438>
35. Zhang F, Smith LP, Blinov ML, Faeder J, Hlavacek WS, Juan Tapia J, et al. Systems biology markup language (SBML) level 3 package: multistate, multicomponent and multicompartments species, version 1, release 2. *J Integr Bioinforma.* 2020;17.
36. Gauges R, Rost U, Sahle S, Wengler K, Bergmann FT. The Systems Biology Markup Language (SBML) Level 3 Package: Layout, Version 1 Core. *J Integr Bioinforma.* 2015;12:267.
37. Bergmann FT, Keating SM, Gauges R, Sahle S, Wengler K. SBML Level 3 package: Render, Version 1, Release 1. *J Integr Bioinforma.* 2018;15.
38. Courtot M, Juty N, Knüpfer C, Waltemath D, Zhukova A, Dräger A, et al. Controlled vocabularies and semantics in systems biology. *Mol Syst Biol.* 2011;7:543.
39. Hoksza D, Gawron P, Ostaszewski M, Hasenauer J, Schneider R. Closing the gap between formats for storing layout information in systems biology. *Brief Bioinform.* 2020;21:1249–60.
40. Balaur I, Roy L, Mazein A, Karaca SG, Dogrusoz U, Barillot E, et al. cd2sbgnml: bidirectional conversion between CellDesigner and SBGN formats. *Bioinforma Oxf Engl.* 2020;36:2620–2.
41. Bohler A, Wu G, Kutmon M, Pradhana LA, Coort SL, Hanspers K, et al. Reactome from a WikiPathways Perspective. *PLoS Comput Biol.* 2016;12:e1004941.
42. Chaouiya C, Bérenguier D, Keating SM, Naldi A, van Iersel MP, Rodriguez N, et al. SBML qualitative models: a model representation format and infrastructure to foster interactions between qualitative modelling formalisms and tools. *BMC Syst Biol.* 2013;7:135.

43. Aghamiri SS, Singh V, Naldi A, Helikar T, Soliman S, Niarakis A. Automated inference of Boolean models from molecular interaction maps using CaSQ. *Bioinforma Oxf Engl*. 2020;36:4473–82.
44. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003;13:2498–504.
45. Naldi A, Hernandez C, Abou-Jaoudé W, Monteiro PT, Chaouiya C, Thieffry D. Logical Modeling and Analysis of Cellular Regulatory Networks With GINsim 3.0. *Front Physiol*. 2018;9:646.
46. Pillich RT, Chen J, Rynkov V, Welker D, Pratt D. NDEx: A Community Resource for Sharing and Publishing of Biological Networks. *Methods Mol Biol Clifton NJ*. 2017;1558:271–301.
47. Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. *Annu Rev Microbiol*. 2019;73:529–57.
48. Chu H, Chan JF-W, Wang Y, Yuen TT-T, Chai Y, Hou Y, et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71:1400–9.
49. Hui KPY, Cheung M-C, Perera RAPM, Ng K-C, Bui CHT, Ho JCW, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med*. 2020;8:687–95.
50. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J*. 2020;55.
51. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infect Dis*. 2020;20:1135–40.
52. Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. *Hypertens Dallas Tex 1979*. 2020;76:1339–49.
53. Swiecki M, Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. *Curr Opin Virol*. 2011;1:463–75.
54. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science*. 2020;369:718–24.
55. Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. *PLoS Pathog*. 2020;16:e1008737.
56. Lee JS, Shin E-C. The type I interferon response in COVID-19: implications for treatment. *Nat Rev Immunol*. 2020;20:585–6.
57. Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe*. 2020;27:870–8.
58. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 2020;172:577–82.
59. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020;26:672–5.

60. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl.* 2020;395:497–506.
61. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, et al. Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:166–70.
62. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet Lond Engl.* 2020;395:507–13.
63. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020;323:1061–9.
64. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg.* 2020;163:3–11.
65. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A.* 2020;117:11727–34.
66. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature.* 2020;581:215–20.
67. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020;181:271-280.e8.
68. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol.* 2020;5:562–9.
69. Amraie R, Napoleon MA, Yin W, Berrigan J, Suder E, Zhao G, et al. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. *BioRxiv Prepr Serv Biol.* 2020;
70. Gao C, Zeng J, Jia N, Stavenhagen K, Matsumoto Y, Zhang H, et al. SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors. *BioRxiv Prepr Serv Biol.* 2020;
71. Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell.* 2020;78:779-784.e5.
72. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cell Mol Immunol.* 2020;17:765–7.
73. Nakagawa K, Lokugamage KG, Makino S. Viral and Cellular mRNA Translation in Coronavirus-Infected Cells. *Adv Virus Res.* 2016;96:165–92.
74. Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. *J Virol.* 2002;76:3697–708.
75. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. *J Virol.* 2004;78:13600–12.
76. Chen S, Jonas F, Shen C, Hilgenfeld R, Higenfeld R. Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. *Protein Cell.* 2010;1:59–74.
77. V'kovski P, Gerber M, Kelly J, Pfaender S, Ebert N, Braga Lagache S, et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. *eLife.* 2019;8.

78. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. *mBio*. 2013;4.
79. Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q, Fisher M, et al. β -Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway. *Cell*. 2020;183:1520-1535.e14.
80. Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, et al. Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. *J Virol*. 2012;86:11745–53.
81. Krähling V, Stein DA, Spiegel M, Weber F, Mühlberger E. Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. *J Virol*. 2009;83:2298–309.
82. DeDiego ML, Nieto-Torres JL, Jiménez-Guardeño JM, Regla-Nava JA, Alvarez E, Oliveros JC, et al. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. *PLoS Pathog*. 2011;7:e1002315.
83. Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. *Nat Rev Immunol*. 2016;16:469–84.
84. Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, et al. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? *Eur J Pharmacol*. 2020;882:173288.
85. Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. *Annu Rev Pathol*. 2015;10:173–94.
86. Senft D, Ronai ZA. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. *Trends Biochem Sci*. 2015;40:141–8.
87. Choi Y, Bowman JW, Jung JU. Autophagy during viral infection - a double-edged sword. *Nat Rev Microbiol*. 2018;16:341–54.
88. Yang J, Zhou R, Ma Z. Autophagy and Energy Metabolism. *Adv Exp Med Biol*. 2019;1206:329–57.
89. Bello-Perez M, Sola I, Novoa B, Klionsky DJ, Falco A. Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. *Cells*. 2020;9.
90. Carmona-Gutierrez D, Bauer MA, Zimmermann A, Kainz K, Hofer SJ, Kroemer G, et al. Digesting the crisis: autophagy and coronaviruses. *Microb Cell Graz Austria*. 2020;7:119–28.
91. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. *Virology*. 2020;35:266–71.
92. Zhang H, Tu J, Cao C, Yang T, Gao L. Proteasome activator PA28 γ -dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein. *Biochem Biophys Res Commun*. 2020;529:251–6.
93. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. *J Infect*. 2020;81:e24–7.
94. Yang N, Shen H-M. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. *Int J Biol Sci*. 2020;16:1724–31.
95. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. *Cell*. 2000;102:1–4.
96. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*.

2007;35:495–516.

97. Diemer C, Schneider M, Schätzl HM, Gilch S. Modulation of Host Cell Death by SARS Coronavirus Proteins. In: Lal SK, editor. *Mol Biol SARS-Coronavirus* [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010 [cited 2020 Oct 22]. p. 231–45. Available from: http://link.springer.com/10.1007/978-3-642-03683-5_14
98. Liu M, Yang Y, Gu C, Yue Y, Wu KK, Wu J, et al. Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2007;21:1586–96.
99. Kanzawa N, Nishigaki K, Hayashi T, Ishii Y, Furukawa S, Niino A, et al. Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-kappaB activation. *FEBS Lett.* 2006;580:6807–12.
100. Chen Y, Feng Z, Diao B, Wang R, Wang G, Wang C, et al. The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 Mar. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.03.27.20045427>
101. Chu H, Zhou J, Wong BH-Y, Li C, Chan JF-W, Cheng Z-S, et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. *J Infect Dis.* 2016;213:904–14.
102. Abreu MT, Arnold ET, Chow JY, Barrett KE. Phosphatidylinositol 3-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells. Implications for inflammatory diarrheal states. *J Biol Chem.* 2001;276:47563–74.
103. Gauthier R, Harnois C, Drolet JF, Reed JC, Vézina A, Vachon PH. Human intestinal epithelial cell survival: differentiation state-specific control mechanisms. *Am J Physiol Cell Physiol.* 2001;280:C1540-1554.
104. Tan Y-X, Tan THP, Lee MJ-R, Tham P-Y, Gunalan V, Druce J, et al. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. *J Virol.* 2007;81:6346–55.
105. Tsoi H, Li L, Chen ZS, Lau K-F, Tsui SKW, Chan HYE. The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1-PKB/Akt signalling. *Biochem J.* 2014;464:439–47.
106. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. *Radiology.* 2020;296:E72–8.
107. Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis. *J Am Coll Radiol JACR.* 2020;17:701–9.
108. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clin Immunol Orlando Fla.* 2020;215:108427.
109. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. *N Engl J Med.* 2017;377:562–72.
110. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130:2620–9.
111. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature.* 2020;584:463–9.
112. Sinha P, Matthay MA, Calfee CS. Is a “Cytokine Storm” Relevant to COVID-19? *JAMA Intern Med.* 2020;

113. Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. *Joint Bone Spine*. 2020;87:191–3.
114. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D a. MPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145–7.
115. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care Lond Engl*. 2020;24:188.
116. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. *Crit Care Lond Engl*. 2020;24:360.
117. Urwyler P, Moser S, Charitos P, Heijnen IAFM, Rudin M, Sommer G, et al. Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System. *Front Immunol*. 2020;11:2072.
118. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res J Lab Clin Med*. 2020;220:1–13.
119. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res*. 2020;126:1456–74.
120. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. *Nat Rev Cardiol*. 2020;17:116–29.
121. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. *Circ Res*. 2020;127:571–87.
122. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. *Clin Microbiol Rev*. 2009;22:240–73, Table of Contents.
123. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell*. 2010;140:805–20.
124. Ding S, Robek MD. Peroxisomal MAVS activates IRF1-mediated IFN- λ production. *Nat Immunol*. 2014;15:700–1.
125. Berthelot J-M, Lioté F. COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. *EBioMedicine*. 2020;56:102801.
126. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*. 2020;181:1036-1045.e9.
127. Lazear HM, Nice TJ, Diamond MS. Interferon- λ : Immune Functions at Barrier Surfaces and Beyond. *Immunity*. 2015;43:15–28.
128. Siu K-L, Kok K-H, Ng M-HJ, Poon VKM, Yuen K-Y, Zheng B-J, et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. *J Biol Chem*. 2009;284:16202–9.
129. Liao Q-J, Ye L-B, Timani KA, Zeng Y-C, She Y-L, Ye L, et al. Activation of NF-kappaB by the full-length nucleocapsid protein of the SARS coronavirus. *Acta Biochim Biophys Sin*. 2005;37:607–12.

130. Li S-W, Wang C-Y, Jou Y-J, Huang S-H, Hsiao L-H, Wan L, et al. SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6. *Int J Mol Sci.* 2016;17.
131. Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. *J Virol.* 2007;81:9812–24.
132. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. *Science.* 2020;
133. Devaraj SG, Wang N, Chen Z, Chen Z, Tseng M, Barretto N, et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. *J Biol Chem.* 2007;282:32208–21.
134. Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. *J Virol.* 2007;81:548–57.
135. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res.* 2020;179:104811.
136. Kuri T, Zhang X, Habjan M, Martínez-Sobrido L, García-Sastre A, Yuan Z, et al. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. *J Gen Virol.* 2009;90:2686–94.
137. Su S, Jiang S. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. *Signal Transduct Target Ther.* 2020;5:71.
138. Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a Protein Causes Endoplasmic Reticulum Stress and Induces Ligand-Independent Downregulation of the Type 1 Interferon Receptor. Ahmed N, editor. *PLoS ONE.* 2009;4:e8342.
139. Wong HH, Fung TS, Fang S, Huang M, Le MT, Liu DX. Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. *Virology.* 2018;515:165–75.
140. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. *Nat Microbiol.* 2019;4:914–24.
141. Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 [Internet]. *Molecular Biology*; 2020 May. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.05.18.102467>
142. Rao M, Dodoo E, Zumla A, Maeurer M. Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies. *Front Microbiol.* 2019;10:962.
143. Kedia-Mehta N, Finlay DK. Competition for nutrients and its role in controlling immune responses. *Nat Commun.* 2019;10:2123.
144. Zhang X, Ding M, Zhu P, Huang H, Zhuang Q, Shen J, et al. New Insights into the Nrf-2/HO-1 Signaling Axis and Its Application in Pediatric Respiratory Diseases. *Oxid Med Cell Longev.* 2019;2019:3214196.
145. Wu B, Wu Y, Tang W. Heme Catabolic Pathway in Inflammation and Immune

Disorders. *Front Pharmacol.* 2019;10:825.

146. Vitali SH, Fernandez-Gonzalez A, Nadkarni J, Kwong A, Rose C, Mitsialis SA, et al. Heme oxygenase-1 dampens the macrophage sterile inflammasome response and regulates its components in the hypoxic lung. *Am J Physiol Lung Cell Mol Physiol.* 2020;318:L125–34.

147. Jung S-S, Moon J-S, Xu J-F, Ifedigbo E, Ryter SW, Choi AMK, et al. Carbon monoxide negatively regulates NLRP3 inflammasome activation in macrophages. *Am J Physiol Lung Cell Mol Physiol.* 2015;308:L1058-1067.

148. Lv J, Su W, Yu Q, Zhang M, Di C, Lin X, et al. Heme oxygenase-1 protects airway epithelium against apoptosis by targeting the proinflammatory NLRP3-RXR axis in asthma. *J Biol Chem.* 2018;293:18454–65.

149. Kim JK, Jin HS, Suh H, Jo E. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling. *Immunol Cell Biol.* 2017;95:584–92.

150. Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. *Front Immunol.* 2020;11:1518.

151. van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. *Front Immunol.* 2020;11:1580.

152. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. *Leukemia.* 2020;34:1726–9.

153. Siu K-L, Yuen K-S, Castaño-Rodríguez C, Ye Z-W, Yeung M-L, Fung S-Y, et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2019;33:8865–77.

154. Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA, Castaño-Rodríguez C, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. *Virology.* 2015;485:330–9.

155. Castaño-Rodríguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JM, et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis. Denison MR, editor. *mBio.* 2018;9:e02325-17, /mbio/9/3/mBio.02325-17.atom.

156. Verdiá-Báguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguilera VM, et al. Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. *Virology.* 2012;432:485–94.

157. Batra N, De Souza C, Batra J, Raetz AG, Yu A-M. The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). *Int J Mol Sci.* 2020;21:6412.

158. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. *Mediators Inflamm.* 2013;2013:391984.

159. Lee S-M, Park HY, Suh Y-S, Yoon EH, Kim J, Jang WH, et al. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. *Proc Natl Acad Sci U S A.* 2017;114:E5881–90.

160. Oh G-S, Pae H-O, Choi B-M, Chae S-C, Lee H-S, Ryu D-G, et al. 3-Hydroxyanthranilic acid, one of metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses

- inducible nitric oxide synthase expression by enhancing heme oxygenase-1 expression. *Biochem Biophys Res Commun*. 2004;320:1156–62.
161. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. *J Biol Chem*. 1994;269:14457–64.
162. Su Y, Chen D, Lausted C, Yuan D, Choi J, Dai C, et al. Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories [Internet]. *Immunology*; 2020 Jul. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.07.27.224063>
163. Yang X, Wang Z, Li X, Liu B, Liu M, Liu L, et al. SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation. *Cancer Res*. 2018;78:372–86.
164. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CFW, Steegborn C. Substrates and Regulation Mechanisms for the Human Mitochondrial Sirtuins Sirt3 and Sirt5. *J Mol Biol*. 2008;382:790–801.
165. Keppeke GD, Chang CC, Peng M, Chen L-Y, Lin W-C, Pai L-M, et al. IMP/GTP balance modulates cytoophidium assembly and IMPDH activity. *Cell Div*. 2018;13:5.
166. Renz A, Widerspich L, Dräger A. FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2. *Zenodo*; 2020 [cited 2020 Oct 22]; Available from: <https://zenodo.org/record/3752641>
167. Oh J, O'Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. *Ther Adv Neurol Disord*. 2014;7:239–52.
168. Hayek S, Pietrancosta N, Hovhannisyan AA, Alves de Sousa R, Bekaddour N, Ermellino L, et al. Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition. *Eur J Med Chem*. 2020;186:111855.
169. Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y, et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. *Protein Cell*. 2020;11:723–39.
170. Chau T-L, Gioia R, Gatot J-S, Patrascu F, Carpentier I, Chapelle J-P, et al. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? *Trends Biochem Sci*. 2008;33:171–80.
171. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. *Sci STKE Signal Transduct Knowl Environ*. 2006;2006:re13.
172. Fang R, Wang C, Jiang Q, Lv M, Gao P, Yu X, et al. NEMO-IKK β Are Essential for IRF3 and NF- κ B Activation in the cGAS-STING Pathway. *J Immunol Baltim Md 1950*. 2017;199:3222–33.
173. Zheng Y, Zhuang M-W, Han L, Zhang J, Nan M-L, Zhan P, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. *Signal Transduct Target Ther*. 2020;5:299.
174. Rubio D, Xu R-H, Remakus S, Krouse TE, Truckenmiller ME, Thapa RJ, et al. Crosstalk between the type 1 interferon and nuclear factor kappa B pathways confers resistance to a lethal virus infection. *Cell Host Microbe*. 2013;13:701–10.
175. Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex. *Protein Cell*. 2014;5:369–81.
176. Smith JA. Regulation of Cytokine Production by the Unfolded Protein Response;

- Implications for Infection and Autoimmunity. *Front Immunol.* 2018;9:422.
177. Wan D, Jiang W, Hao J. Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response. *Front Immunol.* 2020;11:615.
178. Seo GJ, Kim C, Shin W-J, Sklan EH, Eoh H, Jung JU. TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing. *Nat Commun.* 2018;9:613.
179. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. *Proc Natl Acad Sci U S A.* 2008;105:7809-14.
180. Zipeto D, Palmeira J da F, Argañaraz GA, Argañaraz ER. ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19. *Front Immunol.* 2020;11:576745.
181. Kesic MJ, Simmons SO, Bauer R, Jaspers I. Nrf2 expression modifies influenza A entry and replication in nasal epithelial cells. *Free Radic Biol Med.* 2011;51:444-53.
182. Tseng C-K, Hsu S-P, Lin C-K, Wu Y-H, Lee J-C, Young K-C. Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. *Antiviral Res.* 2017;146:191-200.
183. Miao G, Zhao H, Li Y, Ji M, Chen Y, Shi Y, et al. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. *Dev Cell.* 2020;
184. Valencia I, Peiró C, Lorenzo Ó, Sánchez-Ferrer CF, Eckel J, Romacho T. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? *Front Pharmacol.* 2020;11:1161.
185. Hassan SM, Jawad MJ, Ahjel SW, Singh RB, Singh J, Awad SM, et al. The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role? *Med Arch Sarajevo Bosnia Herzeg.* 2020;74:134-8.
186. Attucks OC, Jasmer KJ, Hannink M, Kassis J, Zhong Z, Gupta S, et al. Induction of heme oxygenase I (HMOX1) by HPP-4382: a novel modulator of Bach1 activity. *PloS One.* 2014;9:e101044.
187. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine.* 2020;55:102763.
188. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol.* 2020;17:533-5.
189. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. *Immunology.* 2020;160:261-8.
190. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity.* 2020;52:971-977.e3.
191. Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. *Cells.* 2020;9.
192. Zhang Y-Y, Li B-R, Ning B-T. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. *Front Immunol.* 2020;11:2033.
193. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;71:762-8.

194. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020;8:420–2.
195. Ciccullo A, Borghetti A, Zileri Dal Verme L, Tosoni A, Lombardi F, Garcovich M, et al. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. *Int J Antimicrob Agents*. 2020;56:106017.
196. Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. *Epidemiol Infect*. 2020;148:e139.
197. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J*. 2020;55.
198. Liu D, Cui P, Zeng S, Wang S, Feng X, Xu S, et al. Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study. *EClinicalMedicine*. 2020;25:100471.
199. Salimi S, Hamlyn JM. COVID-19 and Crosstalk With the Hallmarks of Aging. *J Gerontol A Biol Sci Med Sci*. 2020;75:e34–41.
200. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;
201. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol*. 2020;20:442–7.
202. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden’s Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. *Acta Obstet Gynecol Scand*. 2020;99:819–22.
203. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health*. 2020;5:e475–83.
204. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;
205. Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. *Br J Haematol*. 2020;190:24–7.
206. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. *Clin Chim Acta Int J Clin Chem*. 2020;509:220–3.
207. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med*. 2020;383:1522–34.
208. Zaidi FZ, Zaidi ARZ, Abdullah SM, Zaidi SZA. COVID-19 and the ABO blood group connection. *Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis*. 2020;102838.
209. O’Sullivan JM, Ward S, Fogarty H, O’Donnell JS. More on “Association between ABO blood groups and risk of SARS-CoV-2 pneumonia.” *Br J Haematol*. 2020;190:27–8.
210. Dai X. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases. *Eur J Prev Cardiol*. 2020;27:1436–7.
211. Gérard C, Maggipinto G, Minon J-M. COVID-19 and ABO blood group: another viewpoint. *Br J Haematol*. 2020;190:e93–4.

212. Abrams EM, 't Jong GW, Yang CL. Asthma and COVID-19. *CMAJ Can Med Assoc J J Assoc Medicale Can.* 2020;192:E551.
213. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol.* 2020;146:203-206.e3.
214. Song J, Zeng M, Wang H, Qin C, Hou H-Y, Sun Z-Y, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. *Allergy.* 2020;
215. Dong X, Cao Y-Y, Lu X-X, Zhang J-J, Du H, Yan Y-Q, et al. Eleven faces of coronavirus disease 2019. *Allergy.* 2020;75:1699-709.
216. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol.* 2020;59:78-88.
217. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. *J Allergy Clin Immunol.* 2020;146:80-88.e8.
218. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflamm-aging." *Inflamm Res Off J Eur Histamine Res Soc Al.* 2020;69:825-39.
219. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? *Front Immunol.* 2017;8:1960.
220. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol.* 2018;14:576-90.
221. Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, et al. Inflammaging 2018: An update and a model. *Semin Immunol.* 2018;40:1-5.
222. Aiello F, Gallo Afflitto G, Mancino R, Li J-PO, Cesareo M, Giannini C, et al. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. *Eye Lond Engl.* 2020;34:1206-11.
223. Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. *Clin Mol Allergy CMA.* 2017;15:21.
224. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ.* 2020;370:m3249.
225. Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Sci Transl Med.* 2020;12.
226. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children Fare Better than Adults? *Indian J Pediatr.* 2020;87:537-46.
227. Mehta NS, Mytton OT, Mullins EWS, Fowler TA, Falconer CL, Murphy OB, et al. SARS-CoV-2 (COVID-19): What do we know about children? A systematic review. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;
228. Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiolo A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. *Eur J Pediatr.* 2020;179:1029-46.
229. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak

- of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet Lond Engl.* 2020;395:1771–8.
230. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. *J Pediatr Infect Dis Soc.* 2020;9:393–8.
231. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet Lond Engl.* 2020;395:1607–8.
232. Levin M. Childhood Multisystem Inflammatory Syndrome - A New Challenge in the Pandemic. *N Engl J Med.* 2020;383:393–5.
233. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med.* 2020;383:334–46.
234. Li Q, Cao Z, Rahman P. Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. *Mol Genet Genomic Med.* 2020;8:e1344.
235. Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? *Int J Mol Sci.* 2020;21.
236. Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. *J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi.* 2020;53:425–35.
237. Debnath M, Banerjee M, Berk M. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2020;34:8787–95.
238. Englmeier L. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly. *J Biol Regul Homeost Agents.* 2020;34.
239. Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell.* 2020;182:1419-1440.e23.
240. Carter-Timofte ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen N-S, Al-Mousawi A, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. *Front Immunol.* 2020;11:1606.
241. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;
242. Gu W, Yildirimman R, Van der Stuyft E, Verbeeck D, Herzinger S, Satagopam V, et al. Data and knowledge management in translational research: implementation of the eTRIKS platform for the IMI OncoTrack consortium. *BMC Bioinformatics.* 2019;20:164.
243. Bruzzone C, Bizkarguenaga M, Gil-Redondo R, Diercks T, Arana E, García de Vicuña A, et al. SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum. *iScience.* 2020;23:101645.
244. Ehrlich A, Uhl S, Ioannidis K, Hofree M, tenOever BR, Nahmias Y. The SARS-CoV-2 Transcriptional Metabolic Signature in Lung Epithelium. *SSRN Electron J [Internet].* 2020 [cited 2021 Feb 10]; Available from: <https://www.ssrn.com/abstract=3650499>
245. Bae J-S, Park J-M, Lee J, Oh B-C, Jang S-H, Lee YB, et al. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice.

Metabolism. 2017;66:32–44.

246. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients*. 2020;12.

247. Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. *APMIS Acta Pathol Microbiol Immunol Scand*. 2019;127:681–7.

248. Sajuthi SP, DeFord P, Jackson ND, Montgomery MT, Everman JL, Rios CL, et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. *BioRxiv Prepr Serv Biol*. 2020;

249. De Meulder B, Lefaudeux D, Bansal AT, Mazein A, Chaiboonchoe A, Ahmed H, et al. A computational framework for complex disease stratification from multiple large-scale datasets. *BMC Syst Biol*. 2018;12:60.

250. Li C-X, Wheelock CE, Sköld CM, Wheelock ÅM. Integration of multi-omics datasets enables molecular classification of COPD. *Eur Respir J*. 2018;51.

251. Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, et al. Similarity network fusion for aggregating data types on a genomic scale. *Nat Methods*. 2014;11:333–7.

252. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. *Bioinforma Oxf Engl*. 2009;25:2906–12.

253. Singh A, Shannon CP, Gautier B, Rohart F, Vacher M, Tebbutt SJ, et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. *Bioinforma Oxf Engl*. 2019;35:3055–62.

254. Dugourd A, Saez-Rodriguez J. Footprint-based functional analysis of multiomic data. *Curr Opin Syst Biol*. 2019;15:82–90.

255. Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell*. 2020;182:685–712.e19.

256. Treveil A, Bohar B, Sudhakar P, Gul L, Csabai L, Olbei M, et al. ViralLink: An integrated workflow to investigate the effect of SARS-CoV-2 on intracellular signalling and regulatory pathways. *PLoS Comput Biol*. 2021;17:e1008685.

257. Garcia-Alonso L, Holland CH, Ibrahim MM, Turei D, Saez-Rodriguez J. Benchmark and integration of resources for the estimation of human transcription factor activities. *Genome Res*. 2019;29:1363–75.

258. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov*. 2020;6:14.

259. Li J, Guo M, Tian X, Wang X, Yang X, Wu P, et al. Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. *Med N Y N*. 2020;

260. Stukalov A, Girault V, Grass V, Bergant V, Karayel O, Urban C, et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV [Internet]. *Systems Biology*; 2020 Jun. Available from:

<http://biorxiv.org/lookup/doi/10.1101/2020.06.17.156455>

261. Aranda B, Blankenburg H, Kerrien S, Brinkman FSL, Ceol A, Chautard E, et al. PSICQUIC and PSISCORE: accessing and scoring molecular interactions. *Nat Methods*. 2011;8:528–9.

262. Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, et al. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis

- of SARS-CoV-2 infection. *J Transl Med.* 2020;18:233.
263. Hidalgo MR, Cubuk C, Amadoz A, Salavert F, Carbonell-Caballero J, Dopazo J. High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. *Oncotarget.* 2017;8:5160–78.
264. Hernansaiz-Ballesteros RD, Salavert F, Sebastián-León P, Alemán A, Medina I, Dopazo J. Assessing the impact of mutations found in next generation sequencing data over human signaling pathways. *Nucleic Acids Res.* 2015;43:W270-275.
265. Salavert F, Hidalgo MR, Amadoz A, Çubuk C, Medina I, Crespo D, et al. Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models. *Nucleic Acids Res.* 2016;44:W212-216.
266. Liu A, Trairatphisan P, Gjerga E, Didangelos A, Barratt J, Saez-Rodriguez J. From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL. *NPJ Syst Biol Appl.* 2019;5:40.
267. Helikar T, Kowal B, McClenathan S, Bruckner M, Rowley T, Madrahimov A, et al. The Cell Collective: Toward an open and collaborative approach to systems biology. *BMC Syst Biol.* 2012;6:96.
268. Osborne JM, Fletcher AG, Pitt-Francis JM, Maini PK, Gavaghan DJ. Comparing individual-based approaches to modelling the self-organization of multicellular tissues. *PLoS Comput Biol.* 2017;13:e1005387.
269. Wang Y, An G, Becker A, Cockrell C, Collier N, Craig M, et al. Rapid community-driven development of a SARS-CoV-2 tissue simulator. *BioRxiv Prepr Serv Biol.* 2020;
270. Letort G, Montagud A, Stoll G, Heiland R, Barillot E, Macklin P, et al. PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signalling. *Bioinforma Oxf Engl.* 2019;35:1188–96.
271. Ghaffarizadeh A, Heiland R, Friedman SH, Mumenthaler SM, Macklin P. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. *PLoS Comput Biol.* 2018;14:e1005991.
272. Stoll G, Caron B, Viara E, Dugourd A, Zinovyev A, Naldi A, et al. MaBoSS 2.0: an environment for stochastic Boolean modeling. *Bioinforma Oxf Engl.* 2017;33:2226–8.
273. Montagud A, Traynard P, Martignetti L, Bonnet E, Barillot E, Zinovyev A, et al. Conceptual and computational framework for logical modelling of biological networks deregulated in diseases. *Brief Bioinform.* 2019;20:1238–49.
274. Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. *Nat Genet.* 2016;48:838–47.
275. Fink K, Grandvaux N. STAT2 and IRF9: Beyond ISGF3. *JAK-STAT.* 2013;2:e27521.
276. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. IFN β -dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. *EMBO J.* 2013;32:2751–63.
277. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinforma Oxf Engl.* 2010;26:139–40.
278. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinforma Oxf Engl.* 2003;19:185–93.
279. Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. *Signal Transduct Target Ther.*

2020;5:235.

280. Chauhan D, Bartok E, Gaidt MM, Bock FJ, Herrmann J, Seeger JM, et al. BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1 β Maturation in Macrophages. *Cell Rep.* 2018;25:2354-2368.e5.

281. Khan S, Fielding BC, Tan THP, Chou C-F, Shen S, Lim SG, et al. Over-expression of severe acute respiratory syndrome coronavirus 3b protein induces both apoptosis and necrosis in Vero E6 cells. *Virus Res.* 2006;122:20-7.

282. Freeman TC, Raza S, Theocharidis A, Ghazal P. The mEPN scheme: an intuitive and flexible graphical system for rendering biological pathways. *BMC Syst Biol.* 2010;4:65.

283. Livigni A, O'Hara L, Polak ME, Angus T, Wright DW, Smith LB, et al. A graphical and computational modeling platform for biological pathways. *Nat Protoc.* 2018;13:705-22.

284. Wittig U, Rey M, Weidemann A, Kania R, Müller W. SABIO-RK: an updated resource for manually curated biochemical reaction kinetics. *Nucleic Acids Res.* 2018;46:D656-60.